Close correlation of the cardioprotective effect of FK409, a spontaneous NO releaser, with an increase in plasma cyclic GMP level.
Br J Pharmacol
; 113(1): 5-6, 1994 Sep.
Article
em En
| MEDLINE
| ID: mdl-7812632
ABSTRACT
FK409 ((+/-)-(E)-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexeneamide) , which has been reported by us to be a new spontaneous nitric oxide (NO) releaser, prevented myocardial infarction following occlusion and reperfusion in rat coronary artery and increased plasma cyclic GMP level in rats, dose-dependently and significantly at 32 mg kg-1. Isosorbide dinitrate (ISDN), which is the most popular orally active NO donor used in the treatment of ischaemic cardiovascular diseases, did not show significant effects at 32 mg kg-1 in either experiment. Therefore, it is suggested that FK409 can attenuate myocardial injury during ischaemia and reperfusion in contrast to ISDN and a change in plasma cyclic GMP level may serve as an indicator of the cardioprotective effect of NO-releasing drugs.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vasodilatadores
/
Isquemia Miocárdica
/
GMP Cíclico
/
Infarto do Miocárdio
/
Óxido Nítrico
/
Nitrocompostos
Limite:
Animals
Idioma:
En
Revista:
Br J Pharmacol
Ano de publicação:
1994
Tipo de documento:
Article
País de afiliação:
Japão